Fairmount Funds Management LLC Increases Stake in Viridian Therapeutics via Public Offering

On May 11, 2026, Fairmount Funds Management LLC and its affiliate, Fairmount Healthcare Fund II GP LLC, increased their stake in Viridian Therapeutics, Inc. (VRDN) through an underwritten public offering. Fairmount Healthcare Fund II purchased 1,176,470 shares of Common Stock at a price of $17.00 per share, representing an aggregate investment of approximately $20 million. Following this transaction, the reporting persons collectively hold 17,201,800 shares, which includes 5,090,928 shares of Common Stock and 12,110,872 shares issuable upon the conversion of Series A and Series B Preferred Stock. This combined holding represents a 14.04% ownership stake in the company. In connection with the offering, the reporting persons entered into a 60-day lock-up agreement with the underwriters. The shares were acquired for investment purposes using working capital. Fairmount Funds Management LLC serves as the investment manager for the fund and shares voting and dispositive power over the reported securities.